Emergent BioSolutions | Spese Di Vendita E Di Amministrazione





Spese Di Vendita E Di Amministrazione Cambiamento Data
Acadia Pharmaceuticals USD 124.9M 1.24M 2025-09
Akebia Therapeutics USD 25.74M 1.93M 2025-03
ALKERMES USD 171.77M 17.9M 2025-09
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Amarin USD 17.94M 17.86M 2025-09
ANI Pharmaceuticals USD 76.66M 5.11M 2025-09
BioMarin Pharmaceutical USD 223.42M 8.86M 2025-09
Coherus Biosciences USD 26.02M 8.57M 2025-03
Emergent BioSolutions USD 182.8M 82.3M 2023-06
Exact Sciences USD 491.64M 35.94M 2025-09
Exelixis USD 123.02M 19.9M 2025-12
Glaxosmithkline GBP 2.91B 817.89M 2025-09
Heron Therapeutics USD 23.34M 4.18M 2024-09
Ionis Pharmaceuticals USD 86.56M 4.04M 2025-09
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Lexicon Pharmaceuticals USD 39.19M 7.13M 2024-06
Merck USD 2.85B 215M 2025-12
Moderna USD 308M 40M 2025-12
Myriad Genetics USD 129M 1.3M 2025-09
Nektar Therapeutics USD -0.18 0.07 2024-09
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Pacira USD 91.8M 14.6M 2025-09
Pfizer USD 4.08B 894M 2025-12
PTC Therapeutics USD 84.05M 1.22M 2025-09
Sanofi EUR 2.75B 455M 2025-12
Sarepta Therapeutics USD 77.11M 7.22M 2025-09
United Therapeutics USD 152M 60.5M 2025-09
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Xoma USD 11M 2.54M 2024-06


Emergent BioSolutions Spese Di Vendita E Di Amministrazione - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.